What novel therapies are being investigated for the treatment of human leukocyte antigen (HLA) B27–associated acute anterior uveitis (AAU)?

Updated: Oct 30, 2018
  • Author: Anna Luisa Di Lorenzo, MBBCh; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print


Current therapies for uveitis remain nonspecific in their mode of action, and they have a number of adverse effects, as already mentioned. Owing to this, several therapies dealing with immunomodulation have been investigated. Two promising treatments involve antitumor necrosis factor alpha (anti-TNF-alpha) and the use of HLA-B27 oral tolerance therapy. TNF-alpha has been shown to be a critical inflammatory instigator in the pathogenesis of various forms of uveitis, including AAU, in both animal studies and human experimental studies. In view of this, investigations were carried out to examine the efficacy and safety of using anti-TNF-alpha in the treatment of various forms of uveitis with favorable results. Infliximab is a murine-human chimeric monoclonal antibody directed against human TNF-alpha. It has been shown to be a rapid, effective, and safe therapy of vision-threatening ocular inflammation in Behcet disease and refractory posterior uveitis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!